| Title |
Monotherapy or Combination Therapy for Fibromyalgia Treatment?
|
|---|---|
| Published in |
Current Rheumatology Reports, July 2012
|
| DOI | 10.1007/s11926-012-0278-y |
| Pubmed ID | |
| Authors |
Elena Pita Calandre, Fernando Rico-Villademoros, Carmen María Rodríguez-López |
| Abstract |
Fibromyalgia is a chronic pain disease whose clinical symptomatology also includes different symptom domains: fatigue, sleep disturbances, morning stiffness, dyscognition, and psychological distress. These associated symptoms usually vary in frequency and intensity from patient to patient. Because the efficacy of monotherapy is limited, more severely affected patients frequently require drug combinations. There is, however, scarce scientific information concerning the benefits and risks of such combinations. To date, only ten studies investigating the efficacy and tolerability of two-drug combinations have been published; some of these studies are old and/or studied drugs that are now known to be of little or no interest in fibromyalgia management. Thus, when polytherapy is considered, therapeutic decisions must be based on data from monotherapy trials and a sound knowledge of the pharmacological profile of each drug. Well-designed clinical trials exploring specific drug combinations selected on the basis of potential additive or synergistic effects should be performed. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 33% |
| United States | 1 | 33% |
| United Kingdom | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | <1% |
| Unknown | 104 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Unspecified | 19 | 18% |
| Student > Master | 17 | 16% |
| Researcher | 11 | 10% |
| Student > Bachelor | 7 | 7% |
| Student > Doctoral Student | 6 | 6% |
| Other | 20 | 19% |
| Unknown | 25 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 27% |
| Unspecified | 19 | 18% |
| Nursing and Health Professions | 10 | 10% |
| Psychology | 6 | 6% |
| Agricultural and Biological Sciences | 4 | 4% |
| Other | 14 | 13% |
| Unknown | 24 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 December 2023.
All research outputs
#3,945,031
of 22,671,366 outputs
Outputs from Current Rheumatology Reports
#142
of 705 outputs
Outputs of similar age
#27,471
of 163,884 outputs
Outputs of similar age from Current Rheumatology Reports
#2
of 11 outputs
Altmetric has tracked 22,671,366 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 705 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.1. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 163,884 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.